Drug-eluting stents not associated with worse long-term outcome than bare-metal stents
This article has no abstract so we have provided the first paragraph of the full text.
The use of drug-eluting stents (DESs) in percutaneous coronary intervention reduces the occurrence of restenosis and, consequently, the need for repeat revascularization. The initial randomized studies of DESs focused on their efficacy at reducing restenosis, and were, therefore, inadequately powered to assess differences in the occurrence of less frequent events such as death, myocardial infarction and stent thrombosis. Recent studies have indicated that DESs might be associated with a worse long-term prognosis than bare-metal stents (BMSs). In response to this concern, three research groups have carried out pooled analyses to examine the long-term safety of DESs, as compared with BMSs.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
